针对《癌症治疗药物甲磺酸伊马替尼的心脏毒性》一文的回复。 - Suppr

Suppr

超能文献

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

作者信息

Hatfield Alan, Owen Samantha, Pilot Paul Richard

出版信息

Nat Med. 2007 Jan;13(1):13; author reply 15-6. doi: 10.1038/nm0107-13a.

DOI:10.1038/nm0107-13a

PMID:17206118

Abstract

摘要

相似文献

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Nat Med. 2007 Jan;13(1):13; author reply 15-6. doi: 10.1038/nm0107-13a.

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Nat Med. 2007 Jan;13(1):15; author reply 15-6. doi: 10.1038/nm0107-15a.

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Nat Med. 2007 Jan;13(1):14; author reply 15-6. doi: 10.1038/nm0107-14.

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Nat Med. 2007 Jan;13(1):13-4; author reply 15-6. doi: 10.1038/nm0107-13b.

Cardiotoxicity of imatinib: At the heart of the problem.

Leuk Res. 2011 Jan;35(1):36-7. doi: 10.1016/j.leukres.2010.09.021.

Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

Ann Hematol. 2004;83 Suppl 1:S65-6. doi: 10.1007/s00277-004-0850-2.

Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.

Oncologist. 2005 Jun-Jul;10(6):457-8. doi: 10.1634/theoncologist.10-6-457.

Imatinib mesylate.

Rev Gastroenterol Disord. 2002;2(2):75-86.

J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8.

Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.

Haematologica. 2004 Sep;89(9):ECR32.

引用本文的文献

Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring.

Eur J Clin Pharmacol. 2024 Jul;80(7):1061-1068. doi: 10.1007/s00228-024-03675-9. Epub 2024 Mar 27.

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network.

Front Cardiovasc Med. 2023 Feb 7;10:888366. doi: 10.3389/fcvm.2023.888366. eCollection 2023.

Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium/Calmodulin Dependent Protein Kinase II.

Front Cardiovasc Med. 2021 Feb 1;7:630480. doi: 10.3389/fcvm.2020.630480. eCollection 2020.

Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib.

Heart Fail Rev. 2020 May;25(3):447-456. doi: 10.1007/s10741-020-09926-y.

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.

World J Gastroenterol. 2018 Dec 14;24(46):5189-5202. doi: 10.3748/wjg.v24.i46.5189.

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.

Vasc Health Risk Manag. 2017 Aug 4;13:293-303. doi: 10.2147/VHRM.S108874. eCollection 2017.

From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Antioxid Redox Signal. 2019 Jun 20;30(18):2110-2153. doi: 10.1089/ars.2016.6930. Epub 2017 May 15.

Cardiotoxicity associated with targeted cancer therapies.

Mol Clin Oncol. 2016 May;4(5):675-681. doi: 10.3892/mco.2016.800. Epub 2016 Mar 3.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28.

Cardiac effects of anticancer therapy in the elderly.

J Clin Oncol. 2014 Aug 20;32(24):2654-61. doi: 10.1200/JCO.2013.55.0459. Epub 2014 Jul 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验